Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth.
Lin YC, Keenan K, Gong J, Panjwani N, Avolio J, Lin F, Adam D, Barrett P, Bégin S, Berthiaume Y, Bilodeau L, Bjornson C, Brusky J, Burgess C, Chilvers M, Consunji-Araneta R, Côté-Maurais G, Dale A, Donnelly C, Fairservice L, Griffin K, Henderson N, Hillaby A, Hughes D, Iqbal S, Itterman J, Jackson M, Karlsen E, Kosteniuk L, Lazosky L, Leung W, Levesque V, Maille É, Mateos-Corral D, McMahon V, Merjaneh M, Morrison N, Parkins M, Pike J, Price A, Quon BS, Reisman J, Smith C, Smith MJ, Vadeboncoeur N, Veniott D, Viczko T, Wilcox P, van Wylick R, Cutting G, Tullis E, Ratjen F, Rommens JM, Sun L, Solomon M, Stephenson AL, Brochiero E, Blackman S, Corvol H, Strug LJ. Lin YC, et al. Among authors: bilodeau l. Genet Med. 2021 Nov;23(11):2235-2236. doi: 10.1038/s41436-021-01281-z. Genet Med. 2021. PMID: 34389817 Free PMC article. No abstract available.
Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth.
Lin YC, Keenan K, Gong J, Panjwani N, Avolio J, Lin F, Adam D, Barrett P, Bégin S, Berthiaume Y, Bilodeau L, Bjornson C, Brusky J, Burgess C, Chilvers M, Consunji-Araneta R, Côté-Maurais G, Dale A, Donnelly C, Fairservice L, Griffin K, Henderson N, Hillaby A, Hughes D, Iqbal S, Itterman J, Jackson M, Karlsen E, Kosteniuk L, Lazosky L, Leung W, Levesque V, Maille É, Mateos-Corral D, McMahon V, Merjaneh M, Morrison N, Parkins M, Pike J, Price A, Quon BS, Reisman J, Smith C, Smith MJ, Vadeboncoeur N, Veniott D, Viczko T, Wilcox P, van Wylick R, Cutting G, Tullis E, Ratjen F, Rommens JM, Sun L, Solomon M, Stephenson AL, Brochiero E, Blackman S, Corvol H, Strug LJ. Lin YC, et al. Among authors: bilodeau l. Genet Med. 2021 May;23(5):927-933. doi: 10.1038/s41436-020-01073-x. Epub 2021 Jan 26. Genet Med. 2021. PMID: 33500570 Free PMC article.
Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.
Gong J, He G, Wang C, Bartlett C, Panjwani N, Mastromatteo S, Lin F, Keenan K, Avolio J, Halevy A, Shaw M, Esmaeili M, Côté-Maurais G, Adam D, Bégin S, Bjornson C, Chilvers M, Reisman J, Price A, Parkins M, van Wylick R, Berthiaume Y, Bilodeau L, Mateos-Corral D, Hughes D, Smith MJ, Morrison N, Brusky J, Tullis E, Stephenson AL, Quon BS, Wilcox P, Leung WM, Solomon M, Sun L, Brochiero E, Moraes TJ, Gonska T, Ratjen F, Rommens JM, Strug LJ. Gong J, et al. Among authors: bilodeau l. NPJ Genom Med. 2022 Apr 8;7(1):28. doi: 10.1038/s41525-022-00299-9. NPJ Genom Med. 2022. PMID: 35396391 Free PMC article.
A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.
Waters V, Shaw M, Perrem L, Quon BS, Tullis E, Solomon M, Rayment JH, Lavoie A, Tse SM, Daigneault P, Bilodeau L, Price A, Nicholson M, Chin M, Parkins M, McKinney ML, Tam JS, Stanojevic S, Grasemann H, Ratjen F; (PIPE Study Investigators). Waters V, et al. Among authors: bilodeau l. Eur Respir J. 2024 Jun 6;63(6):2302278. doi: 10.1183/13993003.02278-2023. Print 2024 Jun. Eur Respir J. 2024. PMID: 38697648 Clinical Trial.
Cystic Fibrosis Related Diabetes: a first Canadian Clinical Practice guideline.
Coriati A, Potter K, Gilmour J, Lam G, Nichols C, Lands L, Doyle MA, Boudreau V, Alexandre-Heymann L, McKinney M, Sherifali D, Senior P, Rabasa-Lhoret R; Canadian CFRD working group. Coriati A, et al. Can J Diabetes. 2024 Sep 9:S1499-2671(24)00178-3. doi: 10.1016/j.jcjd.2024.09.001. Online ahead of print. Can J Diabetes. 2024. PMID: 39260688 Free article. No abstract available.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis.
Konstan MW, Polineni D, Chmiel JF, Bilodeau L, Middleton PG, Matouk E, Houle JM, Pislariu R, Colin P, Kianicka I, Potvin D, Radzioch D, Kotsimbos T, Zuckerman JB, Nasr SZ, Liou TG, Lands LC; study Investigators. Konstan MW, et al. Among authors: bilodeau l. J Cyst Fibros. 2024 Jul 9:S1569-1993(24)00789-6. doi: 10.1016/j.jcf.2024.07.004. Online ahead of print. J Cyst Fibros. 2024. PMID: 38987119
124 results